Speaker Profile
M.D., Co-Founder and Chief Medical Officer, Adela
Biography
Dr. Hartman is a leader in oncology diagnostics with over 20 years of experience developing clinical cancer tests. Leveraging her expertise across the continuum of care, from early detection to minimal residual disease monitoring, she has spearheaded pivotal trials in risk stratification, cancer screening, and cancer management during her leadership roles at Myriad Genetics and GRAIL. Driven by a passion for innovation, Dr. Hartman co founded Adela to pioneer a high performing liquid biopsy utilizing whole methylome technology. With diverse expertise in clinical development, product development and diagnostic platforms, she is translating her deep knowledge into transformative molecular approaches for early diagnosis and tailored treatment.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair: Victor Velculescu, Johns Hopkins
PMWC Award Ceremony
• Pioneer Honoree: Klaus Pantel, UKE & ELBS
• Luminary: Rebecca Fitzgerald, University of Cambridge
Keynote
• Klaus Pantel, UKE & ELBS
Advancing Minimal Residual Disease (MRD) Detection through cfDNA and cfRNA Profiling
• Chair: Luis Diaz, MSKCC
• Anne-Renee Hartman, Adela
Early Cancer Detection / Regulatory / Population Health
• Peter Bach, DELFI Diagnostics
• Joshua J. Ofman, GRAIL
Role of AI in Liquid Biopsies and Cancer Detection
• Chair: Amoolya Singh, DELFI Diagnostics
